Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Source:http://linkedlifedata.com/resource/pubmed/id/10611340

Proc. Natl. Acad. Sci. U.S.A. 1999 Dec 21 96 26 15074-9

Download in:

View as

Triples

General Info

PMID
10611340